American Journal of Kidney Diseases
Volume 47, Issue 1 , Pages 171-173 , January 2006

Target Hemoglobin Level for EPO Therapy in CKD

References 

  1. Muirhead N , Bargman J , Burgess E , et al.   Evidence-based recommendations for the clinical use of recombinant human erythropoietin . Am J Kidney Dis . 1995;26(suppl 1):S1–S24
  2. Volkova N , Arab L . Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients . Am J Kidney Dis . 2006;47:24–36
  3. Collins AJ , Li S , St Peter W , et al.   Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39% . J Am Soc Nephrol . 2001;12:2465–2473
  4. Li S , Collins AJ . Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients . Kidney Int . 2004;65:626–633
  5. Foley RN , Parfrey PS , Kent GM , Harnett JD , Murray DC , Barre PE . Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease . J Am Soc Nephrol . 2000;11:912–916
  6. Foley RN , Parfrey PS , Harnett JD , Kent GM , Murray DC , Barre PE . The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease . Am J Kidney Dis . 1996;28:53–61
  7. Besarab A , Bolton WK , Browne JK , et al.   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin . N Engl J Med . 1998;339:584–590
  8. Greene T , Daugirdas J , Depner T , et al.   Association of achieved dialysis dose with mortality in the hemodialysis study (an example of “dose-targeting bias.”) . J Am Soc Nephrol . 2005;16:3371–3380
  9. Foley RN , Parfrey PS , Morgan J , et al.   Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy . Kidney Int . 2000;58:1325–1335
  10. Parfrey PS , Foley RN , Wittreich BH , Sullivan DJ , Zagari MJ , Frei D . Double blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic cardiac disease . J Am Soc Nephrol . 2005;16:2180–2189
  11. Tonelli M , Winkelmeyer WC , Jindal KK , Owen WF , Manns BJ . The cost effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients . Kidney Int . 2003;64:295–304
  12. Leyland-Jones B . BEST Investigators (Breast cancer trial with erythropoietin terminated unexpectedly) . Lancet Oncol . 2003;5:206–207
  13. Henke M , Laszig R , Rube C , et al.   Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy (Randomized, double-blind, placebo-controlled trial) . Lancet . 2003;362:1255–1260
  14. Keith DS , Nichols GA , Gullion CM , et al.   Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization . Arch Intern Med . 2004;164:659–663
  15. Abramson JL , Jurkovitz CT , Vaccarino V , et al.   Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population (The ARIC Study) . Kidney Int . 2003;64:610–615
  16. Pfeffer MA , Solomon SD , Ivanovich P , Singh AK , McMurray JJ . Uncertainty in the treatment of anemia of chronic kidney disease . Rev Cardiovasc Med . 2005;6(suppl 3):S35–S41
  17. Mix TC , Brenner RM , Cooper ME , et al.   Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) (Evolving the management of cardiovascular risk in patients with chronic kidney disease) . Am Heart J . 2005;149:408–413

 Conflict of interest: Dr Parfrey has been a member of scientific committees and undertaken research funded by makers of erythropoietin products, including Amgen, Johnson & Johnson, Jansen-Ortho, and Roche.

PII: S0272-6386(05)01678-1

doi: 10.1053/j.ajkd.2005.11.001

American Journal of Kidney Diseases
Volume 47, Issue 1 , Pages 171-173 , January 2006

Article Tools